| Literature DB >> 35138426 |
Dennis Den Hartog1, Saskia H Van Bergen1, Kiran C Mahabier1, Michael H J Verhofstad1, Esther M M Van Lieshout2.
Abstract
PURPOSE: The best treatment of humeral shaft fractures in adults is still under debate. This study aimed to compare functional and clinical outcome of operative versus nonoperative treatment in adult patients with a humeral shaft fracture. We hypothesized that operative treatment would result in earlier functional recovery.Entities:
Keywords: Fracture; Humerus; Nonoperative; Outcome; Shaft; Treatment
Mesh:
Year: 2022 PMID: 35138426 PMCID: PMC9360107 DOI: 10.1007/s00068-022-01890-6
Source DB: PubMed Journal: Eur J Trauma Emerg Surg ISSN: 1863-9933 Impact factor: 2.374
Fig. 1Flow chart of the study
Patient, injury, treatment, and admission details of study participants by treatment group
| All ( | Operative ( | Nonoperative ( | |||||
|---|---|---|---|---|---|---|---|
| Patient characteristics | |||||||
| Female | 390 | 227 (58.2%) | 245 | 133 (54.3%) | 145 | 94 (64.8%) | |
| Age (year) | 390 | 57 (40–68) | 245 | 53 (35–66) | 145 | 62 (49–71) | |
| BMI (kg/m2) | 387 | 26.0 (23.4–29.7) | 244 | 26.1 (23.4–29.9) | 143 | 25.8 (23.4–29.6) | 0.928 |
| Smoking | 390 | 81 (20.8%) | 245 | 55 (22.4%) | 145 | 26 (17.9%) | 0.304 |
| ASA 3 or 4 | 390 | 25 (6.4%) | 245 | 13 (5.3%) | 145 | 12 (8.3%) | 0.286 |
| Comorbidities | |||||||
| Any | 390 | 198 (50.8%) | 245 | 115 (46.9%) | 145 | 83 (57.2%) | 0.059 |
| Diabetes | 390 | 30 (7.7%) | 245 | 18 (7.3%) | 145 | 12 (8.3%) | 0.844 |
| Osteoarthritis | 390 | 32 (8.2%) | 245 | 15 (6.1%) | 145 | 17 (11.7%) | 0.058 |
| Osteoporosis or osteopenia | 390 | 6 (1.5%) | 245 | 1 (0.4%) | 145 | 5 (3.4%) | |
| Medication use | 390 | 208 (53.3%) | 245 | 127 (51.8%) | 145 | 81 (55.9%) | 0.463 |
| Number of medications | 208 | 3 (1–5) | 127 | 2 (1–4) | 81 | 3 (1–5) | 0.225 |
| Injury characteristics | |||||||
| Dominant side affected | 390 | 189 (48.5%) | 245 | 116 (47.3%) | 145 | 73 (50.3%) | 0.601 |
| Fracture classification | |||||||
| A1 | 390 | 108 (27.7%) | 245 | 57 (23.3%) | 145 | 51 (35.2%) | |
| A2 | 66 (16.9%) | 43 (17.6%) | 23 (15.9%) | ||||
| A3 | 89 (22.8%) | 71 (29.0%) | 18 (12.4%) | ||||
| B1 | 93 (23.8%) | 51 (20.8%) | 42 (29.0%) | ||||
| B2 | 15 (3.8%) | 10 (4.1%) | 5 (3.4%) | ||||
| B3 | 19 (4.9%) | 13 (5.3%) | 6 (4.1%) | ||||
| Radial nerve palsy at presentation | 390 | 16 (4.1%) | 245 | 13 (5.3%) | 145 | 3 (2.1%) | 0.185 |
| Additional injuries | 390 | 37 (9.5%) | 245 | 26 (10.6%) | 145 | 11 (7.6%) | 0.374 |
| Ipsilateral arm | 390 | 7 (1.8%) | 245 | 6 (2.4%) | 145 | 1 (0.7%) | 0.266 |
| Contralateral arm | 390 | 5 (1.3%) | 245 | 4 (1.6%) | 145 | 1 (0.7%) | 0.655 |
| Admission and follow-up characteristics | |||||||
| Hospital | |||||||
| Admission | 390 | 271 (69.5%) | 245 | 245 (100.0%) | 145 | 26 (17.9%) | |
| LOS (days) | 271 | 2 (2–4) | 245 | 2 (2–4) | 26 | 2 (2–3) | 0.830 |
| Discharge disposition | |||||||
| Home | 271 | 258 (95.2%) | 245 | 235 (95.9%) | 26 | 23 (88.5%) | 0.093 |
| Care hotel | 8 (3.0%) | 6 (2.4%) | 2 (7.7%) | ||||
| Elderly care facility | 2 (0.7%) | 1 (0.4%) | 1 (3.8%) | ||||
| Rehabilitation center | 3 (1.1%) | 3 (1.2%) | 0 (0.0%) | ||||
| Other care facility admission | 390 | 13 (3.3%) | 245 | 8 (3.3%) | 145 | 5 (3.4%) | 1.000 |
| Nursing home, LOS (days) | 1 | 30 (30–30) | 1 | 30 (30–30) | 0 | N.A | N.A |
| Care hotel, LOS (days) | 7 | 10 (5–30) | 4 | 8 (5–25) | 3 | 21 (3–21) | 0.721 |
| Elderly care facility, LOS (days) | 4 | 35 (23–84) | 1 | 21 (21–21) | 3 | 42 (28–42) | 0.180 |
| Rehabilitation clinic, LOS (days) | 3 | 25 (24–25) | 3 | 25 (24–25) | 0 | N.A | N.A |
| Physical therapy (number of sessions) | 337 | 24 (12–45) | 217 | 25 (13–48) | 120 | 22 (12–42) | 0.307 |
P-values <0.05 are shown in boldface
Data are presented as N (%) or median (P25–P75)
ASA American Society of Anesthesiologists' classification, BMI body mass index, LOS length of stay
*N represents the number of patients for whom data were available per follow-up moment
Fig. 2Changes in functional outcome scores, pain, and activity resumption over time by treatment group. A Disabilities of the Arm, Shoulder, and Hand (DASH) score, B Constant–Murley score of the affected arm, C pain (VAS, Visual Analog Scale) of the affected side, D the extent to which patients resumed their activities at the pre-trauma level (Numeric Rating Scale, NRS) over time. Higher scores represent more disability (DASH), a better function (Constant-Murley), more pain (VAS), and level of activity resumption (NRS, Numeric Rating Scale). Data are shown as estimated marginal mean with the corresponding 95% confidence interval, adjusted for age, gender, and fracture type, as emerging from the multivariable analysis. Blue lines represent the operative group; red lines represent the nonoperative group. In panel C, the dashed lines represent the contralateral side. *p < 0.05 (Bonferroni test).
Treatment effect over time and outcome at three months follow-up by treatment group
| Effect | Outcome at three months follow-up | |||
|---|---|---|---|---|
| Operative ( | Nonoperative ( | |||
| Patient-reported outcome measures | ||||
| DASH | 11.79 ( | 27.30 ( | ||
| Constant–Murley | 19.45 ( | 44.23 ( | ||
| Pain | 0.50 (0.479 | 3.98 ( | 2.7 (2.3–3.0) | 2.4 (1.9–2.8) |
| Activity resumption | 3.69 (0.056) | 7.79 ( | ||
| HR-QoL | ||||
| SF-36 | ||||
| PCS | 0.49 (0.484) | 7.36 ( | 43 (42–44) | 41 (40–43) |
| MCS | 7.80 ( | 1.80 (0.126) | 55 (54–57) | 51 (49–53) |
| EQ-5D | ||||
| US | 6.04 ( | 10.97 ( | 0.77 (0.74–0.80) | 0.72 (0.68–0.75) |
| VAS | 0.96 (0.328) | 1.73 (0.141) | 76 (74–78) | 74 (72–77) |
| Shoulder range of motion (°) | ||||
| Abduction | 45.79 ( | 43.01 ( | ||
| Anteflexion | 67.27 ( | 70.32 ( | ||
| External rotation | 156.03 ( | 81.58 ( | ||
| Internal rotation | 0.32 (0.570) | 0.64 (0.636) | 58 (55–60) | 57 (53–60) |
| Elbow range of motion (°) | ||||
| Flexion | 52.86 ( | 21.11 ( | ||
| Extension deficit | 56.41 ( | 27.60 ( | ||
| Pronation | 42.88 ( | 16.99 ( | 84 (82–85) | 81 (79–83) |
| Supination | 28.64 ( | 22.68 ( | 82 (80–84) | 78 (76–881) |
Changes in recovery pattern were assessed in the multilevel model. Results are shown by the F value for treatment and for the interaction term in the model (treatment * follow-up moment), with their corresponding p value in parenthesis
DASH disabilities of the arm, shoulder, and hand, EQ-5D EuroQoL-5D, HR-QoL health-related quality of life, MCS mental component summary, PCS physical component summary, SF-36 short form-36, US utility score, VAS visual analog scale
Data of the outcome at three months are shown as the estimated marginal mean with 95% confidence interval after three months follow-up adjusted for age, gender, and fracture type. If the intervals did not overlap, this is indicated in bold face. The Constant–Murley score, pain score, and ranges of motion of the shoulder and arm are shown for the affected side. Bold face indicates that the 95% confidence interval of the two treatment groups did not overlap (p < 0.05, Bonferroni test)
Fig. 3Changes in health-related quality of life over time by treatment group. A Short Form-36 (SF-36) Physical Component Summary (SF-36 PCS), B SF-36 Mental Component Summary (SF-36 MCS), C EuroQoL-5D-3L (EQ-5D) utility score (EQ-5D US), and D EQ-5D Visual Analog Scale (EQ-5D VAS) over time. Higher scores represent better quality of life. Data are shown as estimated marginal mean with the corresponding 95% confidence interval, adjusted for age, gender, and fracture type, as emerging from the multivariable analysis. Blue lines represent the operative group; red lines represent the nonoperative group. In panels A and B, the dashed lines represent the mean ± SD (50 ± 10) that was used for normalizing the data. *p < 0.05 (Bonferroni test)
Fig. 4Changes in range of motion of the shoulder over time by treatment group. A Abduction, B anteflexion, C external rotation, and D internal rotation of the shoulder over time. Higher scores represent better range of motion (ROM). Data are shown as estimated marginal mean with the corresponding 95% confidence interval, adjusted for age, gender, and fracture type, as emerging from the multivariable analysis. Blue lines represent the operative group; red lines represent the nonoperative group. Dashed lines represent the contralateral side. *p < 0.05 (Bonferroni test)
Fig. 5Changes in range of motion of the elbow over time by treatment group. A Flexion, B extension, C pronation, and D supination of the elbow over time. Higher scores represent better range of motion (ROM). Data are shown as estimated marginal mean with the corresponding 95% confidence interval, adjusted for age, gender, and fracture type, as emerging from the multivariable analysis. Blue lines represent the operative group; red lines represent the nonoperative group. *p < 0.05 (Bonferroni test)
Work and sports participation pre-trauma and post-trauma resumption of study participants by treatment group
| All ( | Operative ( | Nonoperative ( | |||||
|---|---|---|---|---|---|---|---|
| Paid work ( | 390 | 198 (50.8%) | 245 | 136 (55.5%) | 145 | 62 (42.8%) | |
| Hours per week | 194 | 36 (27–40) | 134 | 38 (32–40) | 60 | 32 (21–40) | |
| Exertional level | |||||||
| Light, mainly sedentary | 198 | 88 (44.4%) | 136 | 64 (47 1%) | 62 | 24 (38.7%) | 0.304 |
| Medium work | 71 (35.9%) | 49 (36.0%) | 22 (35.5%) | ||||
| Heavy or very heavy work | 39 (19.7%) | 23 (16.9%) | 16 (25.8%) | ||||
| Work absence | 196 | 179 (91.3%) | 134 | 123 (91.8%) | 62 | 56 (90.3%) | 0.787 |
| Work days missed | 196 | 30 (13–54) | 134 | 26 (12–49) | 62 | 33 (15–59) | 0.253 |
| Sports or hobby | |||||||
| Sports or hobby (N patients) | 390 | 384 (98.5%) | 245 | 242 (98.8%) | 145 | 142 (97.9%) | 0.675 |
| Hours per week | 378 | 17 (9–31) | 240 | 16 (9–30) | 138 | 19 (9–32) | 0.115 |
| Resumption at 12 months | 241 | 340 (99.7%) | 215 | 214 (99.5%) | 126 | 126 (100.0%) | 1.000 |
P-values <0.05 are shown in boldface
Data are presented as N (%) or median (P25–P75)
*N represents the number of patients for whom data were available per follow-up moment.
Complications and associated secondary surgical intervention by treatment group
| All ( | Operative ( | Nonoperative ( | |||||
|---|---|---|---|---|---|---|---|
| Any complication | 390 | 108 (27.7%) | 245 | 58 (23.7%) | 145 | 50 (34.5%) | |
| Any surgical re-intervention | 390 | 67 (17.2%) | 245 | 30 (12.2%) | 145 | 37 (25.5%) | |
| Malalignment | 390 | 14 (3.6%) | 245 | 0 (0.0%) | 145 | 14 (9.7%) | |
| Osteosynthesis | 11 | N.A. | 11 | N.A. | |||
| Cuff pathology | 390 | 3 (0.8%) | 245 | 3 (1.2%) | 145 | 0 (0.0%) | 0.298 |
| Superficial infection | 390 | 6 (1.5%) | 245 | 5 (2.0%) | 145 | 1 (0.7%) | 0.419 |
| Deep infection | 390 | 1 (0.3%) | 245 | 1 (0.4%) | 145 | 0 (0.0%) | 1.000 |
| Drainage and implant removal | 1 | 1 | N.A. | N.A. | |||
| Implant-related complication | 390 | 26 (6.7%) | 245 | 26 (10.6%) | 145 | 0 (0.0%) | |
| Nail protrusion | 13 | 13 | N.A. | ||||
| Screw protrusion | 8 | 8 | N.A. | ||||
| Screw cutout | 2 | 2 | N.A. | ||||
| Inadequate implant size | 1 | 1 | N.A. | ||||
| Inadequate implant type | 1 | 1 | N.A. | ||||
| Chronic pain | 1 | 1 | N.A. | ||||
| Implant exchange | 3 | 3 | N.A. | N.A. | |||
| Implant removal | 16 | 16 | N.A. | N.A. | |||
| Disproportional pain and disability | 390 | 5 (1.3%) | 245 | 0 (0.0%) | 145 | 5 (3.4%) | |
| Osteosynthesis | 5 | N.A | 5 | N.A. | |||
| Post-operative or persistent radial nerve apraxia | 390 | 12 (3.3%) | 245 | 9 (3.7%) | 145 | 3 (2.1%) | N.A. |
| Osteosynthesis | 1 | 0 | 1 | N.A. | |||
| Osteosynthesis and nerve grafting | 1 | 0 | 1 | N.A. | |||
| Malunion | 390 | 3 (0.8%) | 245 | 0 (0.0%) | 145 | 3 (2.1%) | 0.051 |
| Nonunion | 302 | 49 (16.2%) | 188 | 19 (10.1%) | 114 | 30 (26.3%) | |
| (Revision) osteosynthesis | 30 | 10 | 20 |
P-values <0.05 are shown in boldface
Data are presented as number (%) or as median (P25–P75) and were analyzed using a Chi-squared test and Mann–Whitney U test, respectively
*N represents the number of patients for whom data were available per follow-up moment